354 related articles for article (PubMed ID: 16273638)
21. Fas ligand expression in colon cancer: a possible mechanism of tumor immune privilege.
Zhang W; Ding EX; Wang Q; Zhu DQ; He J; Li YL; Wang YH
World J Gastroenterol; 2005 Jun; 11(23):3632-5. PubMed ID: 15962391
[TBL] [Abstract][Full Text] [Related]
22. [The role of Fas/Fas ligand in tumorgenesis, immune escape, and counterattack in colonic cancer].
Zhu Q; Deng C
Zhonghua Nei Ke Za Zhi; 2002 Jun; 41(6):378-80. PubMed ID: 12137598
[TBL] [Abstract][Full Text] [Related]
23. Survivin enhances Fas ligand expression via up-regulation of specificity protein 1-mediated gene transcription in colon cancer cells.
Asanuma K; Tsuji N; Endoh T; Yagihashi A; Watanabe N
J Immunol; 2004 Mar; 172(6):3922-9. PubMed ID: 15004200
[TBL] [Abstract][Full Text] [Related]
24. Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer.
O'Connell J; Bennett MW; O'Sullivan GC; Roche D; Kelly J; Collins JK; Shanahan F
J Pathol; 1998 Nov; 186(3):240-6. PubMed ID: 10211111
[TBL] [Abstract][Full Text] [Related]
25. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape?
Ni X; Hazarika P; Zhang C; Talpur R; Duvic M
Clin Cancer Res; 2001 Sep; 7(9):2682-92. PubMed ID: 11555580
[TBL] [Abstract][Full Text] [Related]
26. Up-regulation of fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance.
Shimonishi T; Isse K; Shibata F; Aburatani I; Tsuneyama K; Sabit H; Harada K; Miyazaki K; Nakanuma Y
Hepatology; 2000 Oct; 32(4 Pt 1):761-9. PubMed ID: 11003620
[TBL] [Abstract][Full Text] [Related]
27. Fas and Fas ligand expression in tumor cells and in vascular smooth-muscle cells of colonic and renal carcinomas.
Peduto Eberl L; Guillou L; Saraga E; Schröter M; French LE; Tschopp J; Juillerat-Jeanneret L
Int J Cancer; 1999 May; 81(5):772-8. PubMed ID: 10328232
[TBL] [Abstract][Full Text] [Related]
28. Alpha-fetoprotein triggers hepatoma cells escaping from immune surveillance through altering the expression of Fas/FasL and tumor necrosis factor related apoptosis-inducing ligand and its receptor of lymphocytes and liver cancer cells.
Li MS; Ma QL; Chen Q; Liu XH; Li PF; Du GG; Li G
World J Gastroenterol; 2005 May; 11(17):2564-9. PubMed ID: 15849812
[TBL] [Abstract][Full Text] [Related]
29. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas.
Shiraki K; Tsuji N; Shioda T; Isselbacher KJ; Takahashi H
Proc Natl Acad Sci U S A; 1997 Jun; 94(12):6420-5. PubMed ID: 9177233
[TBL] [Abstract][Full Text] [Related]
30. [The "Fas counterattack": a mechanism for immune evasion in human hilar cholangiocarcinomas].
Li Z; Zhang L; Zou S
Zhonghua Yi Xue Za Zhi; 2002 May; 82(9):606-9. PubMed ID: 12133481
[TBL] [Abstract][Full Text] [Related]
31. [Mechanism of immune escape in renal cell carcinoma].
Zheng J; Sun X; Chen J; Jiang F; Li W; Xie S
Zhonghua Zhong Liu Za Zhi; 2002 Jan; 24(1):24-6. PubMed ID: 11977630
[TBL] [Abstract][Full Text] [Related]
32. Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion.
Mitsiades N; Poulaki V; Mastorakos G; Tseleni-Balafouta ST; Kotoula V; Koutras DA; Tsokos M
J Clin Endocrinol Metab; 1999 Aug; 84(8):2924-32. PubMed ID: 10443700
[TBL] [Abstract][Full Text] [Related]
33. Fas ligand expressed in colon cancer is not associated with increased apoptosis of tumor cells in vivo.
Houston A; Waldron-Lynch FD; Bennett MW; Roche D; O'Sullivan GC; Shanahan F; O'Connell J
Int J Cancer; 2003 Nov; 107(2):209-14. PubMed ID: 12949796
[TBL] [Abstract][Full Text] [Related]
34. [Expression of Fas ligand on peritumoral lymphocytes and its association with apoptosis of colorectal carcinomas].
Song E; Chen J; Wang J; Zhang L
Zhonghua Wai Ke Za Zhi; 2000 Jul; 38(7):517-9, 29. PubMed ID: 11832097
[TBL] [Abstract][Full Text] [Related]
35. Expression of fas/fas ligand (fasL) and its involvement in infiltrating lymphocytes in hepatocellular carcinoma (HCC).
Fukuzawa Y; Takahashi K; Furuta K; Tagaya T; Ishikawa T; Wada K; Omoto Y; Koji T; Kakumu S
J Gastroenterol; 2001 Oct; 36(10):681-8. PubMed ID: 11686478
[TBL] [Abstract][Full Text] [Related]
36. A homozygous Fas ligand gene mutation in a patient causes a new type of autoimmune lymphoproliferative syndrome.
Del-Rey M; Ruiz-Contreras J; Bosque A; Calleja S; Gomez-Rial J; Roldan E; Morales P; Serrano A; Anel A; Paz-Artal E; Allende LM
Blood; 2006 Aug; 108(4):1306-12. PubMed ID: 16627752
[TBL] [Abstract][Full Text] [Related]
37. Correlation of Fas/FasL expression to cell apoptosis in Epstein-Barr virus-associated gastric carcinoma.
He D; Xiao L; Chen JN; Liang Q; Shao CK
Chin J Cancer; 2010 Mar; 29(3):283-7. PubMed ID: 20193111
[TBL] [Abstract][Full Text] [Related]
38. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil R; Egle A; Villunger A
Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
[TBL] [Abstract][Full Text] [Related]
39. Resistance to Fas-mediated cell death in BeWo and NJG choriocarcinoma cell lines: implications in immune privilege.
Rajashekhar G; Loganath A; Roy AC; Mongelli JM
Gynecol Oncol; 2003 Oct; 91(1):89-100. PubMed ID: 14529667
[TBL] [Abstract][Full Text] [Related]
40. Fas ligand upregulation is an early event in colonic carcinogenesis.
Bennett MW; O'Connell J; Houston A; Kelly J; O'Sullivan GC; Collins JK; Shanahan F
J Clin Pathol; 2001 Aug; 54(8):598-604. PubMed ID: 11477113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
